scholarly journals Vascular Calcification and Oxidative DNA Damage as Nontraditional Cardiovascular Risk Factors in Chronic Renal Disease

2018 ◽  
Author(s):  
Edith Viridiana Alatorre-Moreno ◽  
José Ignacio Cerrillos-Gutiérrez ◽  
Jorge Andrade-Sierra ◽  
Enrique Rojas-Campos ◽  
Sandra Carrillo-Ibarra ◽  
...  
Keyword(s):  
Risk Factors ◽  
Dna Damage ◽  
Cardiovascular Risk ◽  
Renal Disease ◽  
Cardiovascular Risk Factors ◽  
Vascular Calcification ◽  
Oxidative Dna Damage ◽  
Chronic Renal Disease

MP-13.04: Cardiovascular risk factors in chronic renal disease

Urology ◽  
2007 ◽  
Vol 70 (3) ◽  
pp. 106-107
Author(s):  
J. Wagner ◽  
V. Šerić ◽  
B. Babić-Ivančić ◽  
J. Milas-Ahić ◽  
H. Kuveždić
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Renal Disease ◽  
Cardiovascular Risk Factors ◽  
Chronic Renal Disease

Chronic Renal Disease in Renal Transplant Patients: Management of Cardiovascular Risk Factors

2009 ◽  
Vol 41 (5) ◽  
pp. 1637-1638 ◽  
Author(s):  
G. Fernández-Fresnedo ◽  
C. Gómez-Alamillo ◽  
J.C. Ruiz ◽  
A.L.M. de Francisco ◽  
M. Arias
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Renal Transplant ◽  
Renal Disease ◽  
Cardiovascular Risk Factors ◽  
Chronic Renal Disease ◽  
Transplant Patients ◽  
Renal Transplant Patients

scholarly journals Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease

2002 ◽  
Vol 13 (1) ◽  
pp. 170-176
Author(s):  
Jan T. Kielstein ◽  
Rainer H. Böger ◽  
Stefanie M. Bode-Böger ◽  
Jürgen C. Frölich ◽  
Hermann Haller ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Failure ◽  
Cardiovascular Risk ◽  
Renal Disease ◽  
Serum Creatinine ◽  
Cardiovascular Risk Factors ◽  
Asymmetric Dimethylarginine ◽  
Chronic Renal Disease ◽  
Blood Concentrations ◽  
Moderate Renal Failure

ABSTRACT. In patients with uremia, increased blood concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to the severity of atherosclerosis and to excess cardiovascular mortality. The ADMA levels and several traditional cardiovascular risk factors were assessed in 44 untreated nonsmoking patients with confirmed primary chronic renal disease at different stages of renal disease. True GFR was assessed by means of the inulin-clearance technique. For comparison, nonsmoking subjects matched with respect to age, gender, and body-mass index were examined. Mean plasma ADMA concentration was markedly higher (P < 0.0001) in all patients combined (4.2 ± 0.9 μmol/L) than in control subjects (n = 16; age 45 ± 10 yr; serum creatinine 1.0 ± 0.1 mg/dl; ADMA 1.4 ± 0.7 μmol/L). However, mean ADMA levels were similar in patients with normal renal function (n = 16; age 41 ± 9 yr; serum creatinine 1.1 ± 0.1 mg/dl; GFR 120 ± 14 ml·min−1·1.73 m2; ADMA 4.0 ± 0.7 μmol/L), in patients with moderate renal failure (n = 15; 47 ± 7 yr; 1.8 ± 0.3 mg/dl; 65 ± 10 ml·min−1·1.73 m2; 3.8 ± 0.6 μmol/L) and in patients with advanced renal failure (n = 13; 46 ± 9 yr; 4.2 ± 0.9 mg/dl; 25 ± 4 ml·min−1·1.73 m2; 4.7 ± 1.2 μmol/L). Furthermore, ADMA levels were increased to the same extent in normotensive (n = 17; 4.0 ± 0.8 μmol/L) and in hypertensive (n = 27; 4.2 ± 0.9 μmol/L) patients. In contrast to ADMA, mean total plasma homocysteine concentration were similar in control subjects (10.6 ± 2.9 μmol/L) and in patients with normal GFR (11.0 ± 2.9 μmol/L), but were significantly higher in patients with moderate renal failure (17.7 ± 4.1 μmol/L) and particularly in patients with advanced renal failure (28.2 ± 10.6 μmol/L). Finally, mean total serum cholesterol concentrations were comparable in the control group and in the three groups of patients with renal disease. In contrast to several traditional cardiovascular risk factors, markedly increased blood concentrations of ADMA, a putative biochemical marker of atherosclerosis, are present even in nonsmoking patients without diabetes with incipient primary renal disease. Thus, the early increase of ADMA levels may be of relevance for the excess cardiovascular morbidity and mortality due to arterio- and atherosclerotic complications in patients with renal disease.

The relation of oxidative DNA damage to hypertension and other cardiovascular risk factors in Tanzania

2001 ◽  
Vol 19 (Supplement) ◽  
pp. 529-533 ◽  
Author(s):  
Hiroko Negishi ◽  
Katsumi Ikeda ◽  
Sachiko Kuga ◽  
Takanori Noguchi ◽  
Tomo Kanda ◽  
...  
Keyword(s):  
Risk Factors ◽  
Dna Damage ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Oxidative Dna Damage

scholarly journals Associations of subjective vitality with DNA damage, cardiovascular risk factors and physical performance

2014 ◽  
Vol 213 (1) ◽  
pp. 156-170 ◽  
Author(s):  
S. Maynard ◽  
G. Keijzers ◽  
Å.-M. Hansen ◽  
M. Osler ◽  
D. Molbo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Dna Damage ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Physical Performance ◽  
Subjective Vitality

Fractional excretion of phosphorus and vascular calcification in stage 3 chronic kidney disease

2018 ◽  
Vol 67 (3) ◽  
pp. 674-680 ◽  
Author(s):  
Manuel Jiménez Villodres ◽  
Guillermo García Gutiérrez ◽  
Patricia García Frías ◽  
José Rioja Villodres ◽  
Mónica Martín Velázquez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Chronic Kidney Disease ◽  
Cardiovascular Risk ◽  
Kidney Disease ◽  
Cardiovascular Risk Factors ◽  
Vascular Calcification ◽  
Fractional Excretion ◽  
X Rays ◽  
Abdominal Radiography ◽  
Vascular Comorbidity

The role of renal excretion of Pi in relation to vascular calcification (VC) in patients in the early stages of chronic kidney disease (CKD) is controversial. Thus, we determine the relation between fractional excretion of phosphorus (FEP) and VC, measured using two methods in a cross-sectional study of patients with stage 3 CKD. We recorded demographic data, anthropometry, comorbidities and active treatment. We measured 24-hour urine FEP and, in serum, measured fibroblast growth factor 23 (FGF23), α-Klotho, intact parathyroid hormone (iPTH), calcium and phosphorus. VC was measured by lateral abdominal radiography (Kauppila index (KI)) and CT of the abdominal aorta (measured in Agatston units). In 57% of subjects, abnormal VC was present when measured using CT, and in only 17% using lateral abdominal radiography. Factors associated with VC using CT were age, cardiovascular risk factors, vascular comorbidity, microalbuminuria and levels of FGF23, phosphorus and calcium x phosphorus product (CaxP); although only age (OR 1.25, 95% CI 1.11 to 1.41), smoking (OR 21.2, CI 4.4 to 100) and CaxP (OR 1.21, CI 1.06 to 1.37) maintained the association in a multivariate analysis. By contrast, only age (OR 1.35, 95% CI 1.07 to 1.74), CaxP (OR 1.14, CI 1.13 to 1.92) and FEP (OR 1.07,95% CI 1004 to 1.14) were associated with abnormal VC in the lateral abdominal radiography. In conclusion, in patients with stage 3 CKD, the detection of VC by abdominal CT is more sensitive than conventional X-rays. Moreover, CaxP is associated with cardiovascular risk factors and vascular comorbidity; quantification of FEPi in these patients provides additional clinical information in advanced VC detected by KI.

Sign in / Sign up

Export Citation Format

Share Document